BSE · 532039
Zenotech Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹7 Cr with net profit ₹-3 Cr — a -35.94% net margin, versus -4.34% the period before.
Shareholding
As of 2026-09-30
- Promoter68.84%
- Public31.15%
- DII0.01%
9,959 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.61× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #22 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,74,208 Cr | 80.24 | 9.45 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹50,733 Cr | 44.28 | 4.9 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,232 Cr | 38.09 | 9.55 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹25,813 Cr | 89.56 | 20.04 | 19.14% | 14.89% |
| Shilpa Medicare Ltd. | ₹18,299 Cr | 64.35 | 7.06 | 9.39% | 17.67% |
| Caplin Point Laboratories Ltd. | ₹18,061 Cr | 27.15 | 5.35 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹16,144 Cr | 21.56 | 3.9 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹14,291 Cr | 27.66 | 4.72 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,244 Cr | 52.62 | 6.09 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,615 Cr | 44.43 | 5.6 | 13.31% | 18.57% |
| Zenotech Laboratories Ltd.(this company) | ₹232 Cr | — | 2.51 | -4.28% | -11.67% |
AI analysis
AI-generated · google/gemini-2.5-flashZenotech Laboratories Ltd. has a market capitalization of Rs 292 Cr. The company reported revenue of Rs 44.6 Cr. Its debt-to-equity ratio stands at 0.13.
Positives
- +The debt-to-equity ratio is low at 0.13.
- +Promoter shareholding is substantial at 68.8419%.
- +No promoter pledges have been reported.
Negatives
- −The company has a negative Return on Equity (ROE) of -112.7%.
- −The profit margin is significantly negative at -270.4%.
- −Earnings per share (EPS) is 0.
- −Quarterly net profit was negative Rs 3.15 Cr for March 2026.
Financial Performance
For the period ending March 2025, Zenotech Laboratories Ltd. reported revenue of Rs 44.5957 Cr and a net profit of Rs 5.6129 Cr. In the latest available quarterly results up to March 2026, revenue was Rs 9.88 Cr with a net loss of Rs 3.15 Cr.
Profitability & Returns
The company's Return on Capital Employed (ROCE) is 4.3584%. However, the Return on Equity (ROE) is -112.7%. The profit margin for the company is -270.4%.
Balance Sheet
Zenotech Laboratories Ltd. has a book value of Rs 15.59 per share. The debt-to-equity ratio is 0.13, indicating a low level of debt relative to equity.
Ownership & Pledges
There are no promoter pledges reported for the period ending June 2026.
Data as of — price: 2026-10-30 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Zenotech Laboratories Ltd.share price & fundamentals